To Expand Operations in Panama and Create Local Jobs, Haleon Pharmaceutical Expands Operations
Mulino indicated that this step demonstrates that Panama is an important player as a regional hub for drug manufacturing.
The British pharmaceutical company Haleon announced an investment of over $30 million to expand its operations in Panama, thereby creating new jobs. The announcement was made by the President of the Republic, José Raúl Mulino.
Pharmaceutical Factory in Panama
The plant, located in the Juan Díaz Industrial Park, employs 220 workers who manufacture medications for well-known health product brands such as Panadol, Advil, Sensodyne, and Centrum. President Mulino welcomed this investment, which, once operational, will employ more than 100 additional workers, both directly and indirectly. Mulino arrived accompanied by the Minister of Commerce and Industries, Julio Moltó, to hold a conversation with Haleon’s President for Latin America, Andrés González; the plant manager, Demian Omar; the Director of Corporate Affairs, Mariana Lucema; and Santiago Baptiste, Director of Government Affairs, all pictured above.
Job Opportunities
During the meeting, Mulino learned that the expansion will allow the company to double its production capacity to supply all of Central America, the Caribbean and the rest of Latin America. The president indicated that this step demonstrates that Panama is an important player as a regional hub for the manufacture of medicines and health products. The investment includes the expansion and modernization of the Juan Díaz plant, with improvements to the infrastructure and employee well-being, as well as the addition of a new, state-of-the-art automated packaging line. Among the goals is reaching a production of 900 million paracetamol tablets per year in Panama, for distribution in 25 markets across Latin America and the Caribbean.
